关键词: 吉西他滨, 非霍奇金淋巴瘤, 沙利度胺, 利妥昔单抗, 奥沙利铂

Abstract: ［Abstract］ Objective To investigate the efficacy and toxicities of thalidomide （oral， starting dose 100 mg/d， increase 50 mg per week， up to 200 mg/d， QN， maintain） combined with R?GEMOX regimen （rituximab 375 mg/m2 d0， gemcitabine 1000 mg/m2， d1， d8， oxaliplatin 130 mg/m2 d1） in treatment of relapsed/refractor B?cell Non?Hodgkin′s lymphoma （NHL）. Methods Thirty?six patients with relapsed or refractor B?cell NHL after medication of traditional chemotherapy accepted thalidomide combined with R?GEMOX regimen，the efficacy toxicities was evaluated after two cycles of chemotherapy， the toxicities was evaluated after 1 cycles of chemotherapy. Results Of the 36 cases， 14 patients were in complete remission and 15 in partial remission， resulting in an overall response rate of 80%. Thirteen patients symptom disappeared， and one in 15 cases was alleviated of type B symptoms. The toxicities can be tolerated. Conclusion Thalidomide combined with R?GEMOX regimen was effect for recurrent or refractory B?cell NHL， and the toxicity was mild. This protocol was worthy of clinical application as salvage for relapsed or refractory B?cell NHL.

Key words: thalidomide, oxaliplatin, non?Hodgkin′s lymphoma, rituximab, gemcitabine